ICARS
International Centre for Antimicrobial Resistance Solutions

Robert Skov, MD, Senior Consultant
National AMR Coordinator, Lead of ICARS project team
Statens Serum Institut, Copenhagen, Denmark
Human Cost of AMR – Lives Lost

- Tetanus: 60,000
- Road traffic accidents: 1.2 million
- Measles: 130,000
- Diarrhoeal disease: 1.4 million
- Cholera: 100,000–120,000
- Diabetes: 1.5 million
- AMR now: 700,000 (low estimate)
- AMR in 2050: 10 million

Economic Cost – Global GDP Loss

AMR’s impact on World GDP in trillions of USD

Total GDP loss: $100.2 trillion

TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY: FINAL REPORT AND RECOMMENDATIONS THE REVIEW ON ANTIMICROBIAL RESISTANCE CHAIRED BY JIM O’NEILL MAY 2016
IMPLICATIONS FOR POVERTY ERADICATION AND STABILITY

Final Report

DRUG-RESISTANT INFECTIONS
A Threat to Our Economic Future

Low AMR: global GDP falls short by 1.1 percent annually by 2050, shortfall exceeds $1 trillion annually after 2030

High AMR: global GDP falls short by 3.8 percent annually by 2050, shortfall reaches $3.4 trillion annually after 2030

Annual increase in number of people living under $1.90/day (purchasing power parity), in millions

- Low-AMR: 1.5 million in 2030, 6.2 million in 2050
- High-AMR: 5.4 million in 2030, 18.7 million in 2050

Additional people falling into extreme poverty: nearly 8 million by 2030 in the low-AMR case; more than 28 million by 2050 in the high-AMR case.
AMR is not just as a public health or agricultural challenge, but an adaptive development challenge (problem of development)

• AMR is a development challenge that will disproportionately affect low- and middle- income countries from an economic and social perspective
• Failure to address AMR will negatively affect some SDGs; also, the pursuit of some SDGs will help combating AMR
Cumulative savings of extra health care costs to 2030 are $4 trillion if “low-AMR” case is avoided and $11 trillion if “high-AMR” case is avoided.
Investment in AMR containment gives high economic rate of return

- Test of expected economic rate of return is unambiguously satisfied (31% - 88%)
- Even a partial containment of AMR is a highly productive investment. Reducing AMR by just 10% (from ‘low AMR’ case) generates cumulative expected benefits of $2 trillion (3.5% discount rate), which more than justifies the $200 billion investment.
- These investments should be the highest priority among public sector investments

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Rate of Return</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Low-AMR Impact</strong></td>
<td></td>
</tr>
<tr>
<td>10% containment</td>
<td>31%</td>
</tr>
<tr>
<td>25% containment</td>
<td>45%</td>
</tr>
<tr>
<td>50% containment</td>
<td>58%</td>
</tr>
<tr>
<td>75% containment</td>
<td>66%</td>
</tr>
<tr>
<td><strong>High-AMR Impact</strong></td>
<td></td>
</tr>
<tr>
<td>10% containment</td>
<td>47%</td>
</tr>
<tr>
<td>Reach low-AMR</td>
<td>84%</td>
</tr>
<tr>
<td>75% containment</td>
<td>88%</td>
</tr>
</tbody>
</table>

Source: Simulation results and authors’ calculations.
AMR – a wicked problem!

AMR respects neither sectors nor borders.

The ever growing human population as well as the livestock production increases the demand for antibiotics.

In several countries lack of access to antibiotics causes more deaths than infections due to AMR bacteria.
Actions against AMR

WHO, FAO, OIE, UNEP (Tripartite+) together with key organizations are developing the necessary policy frameworks for action globally.

The global policy frameworks are translated into the national action plans in the majority of countries.

Several initiatives by the Tripartite+, countries, NGOs and research institutions are ongoing or initiated these years.
Despite growing evidence of the efficacy of numerous AMR interventions, there is little understanding of how to deliver those interventions effectively in diverse settings and within the wide range of existing health systems. Implementation issues often arise as a result of contextual factors that policy-makers and health system managers may not even have considered. Implementation research is crucial for improving our understanding of the challenges we face in confronting the real world by broadening and deepening our understanding of these real-world factors and how they impact implementation. Implementation research is of immense value in shining a light on the often bumpy interface between what can be achieved in theory and what happens in practice.
Traditional wisdom for solving complex problems: the ‘waterfall’

Tame problems
Opportunity-driven problem solving: the “jagged line of learning”
Several low- and middle income countries (LMIC) struggle with implementation of their AMR action plans as well as to find feasible solutions to mitigate the problems of AMR.

There is a need for an international research centre focusing on implementation and solutions in LMIC.
Why Denmark

Denmark has worked “One Health” for 25 years with monitoring of AMU and AMR in human and veterinary bacteria since 1995
• Merged the National Vet Institute and the Statens Serum Institut

Denmark has a large livestock production with experience in the cooperation of authorities with farmers, vets and companies leading to a fairly low AMU and AMR

Denmark has experiences in AMR projects in LMICs with a high degree of local involvement
ICARS Vision

We envisage a world where resistance to antimicrobial drugs no longer poses an urgent threat, and antimicrobial drugs are safeguarded to support the achievement of the Sustainable Development Goals, including human and animal health, welfare, equity and economic growth.
ICARS Mission

The ICARS centre will act as an independent global knowledge node for generating, aggregating and disseminating evidence on antimicrobial drug resistance and support the development of feasible context-specific solutions for its containment.
ICARS’ scope

Implementation and solution driven research are key objectives for ICARS

- Multidisciplinary as well as interdisciplinary
- Evidence based
- Work in a One Health approach cutting across human, livestock and plants, as well as the environment
- Will serve as an independent global knowledge node collecting existing and novel experiences gained from implementation research across scientific disciplines

Focus on low- and middle-income countries

AMR Specific as well as AMR Sensitive issues
ICARS scope

Support the translation of policies into evidence-based practices

Will work with strong local participation to secure development of contextual and feasible solutions for the individual country/region

• Bottom up approach

Will be a learning organization and will evaluate processes and impact of interventions

• Failure in interventions, may be due to the process rather than the rationale
ICARS’ formation

Nov 2017 Initial contact between Denmark and the World Bank on AMR

April 2018 WB visits Denmark

July 2018: Initial Workshop on creating an AMR centre in Denmark

Fall 2018: Concept Note developed, Denmark decides to take the initiative for establishing ICARS

November 2018: MoU between Denmark and CGIAR

November 2018: First public announcement of ICARS – Call for Action conference in Accra, Ghana

December- February 2019: Development of a draft for Initial Work Program (IWP)

February 2019: Participation in opening of the CGIAR AMR Hub

• ICARS will be part of the managing board of the AMR Hub

February 2019: ICARS Workshop on the IWP in Washington
Road ahead

March 2019: Adjustment of IWP

April 2019: Presentation of ICARS at the margin of the WB Spring Meeting
  • Identification of strategic funding partners (countries, foundations)

Autumn 2019: ICARS transforms from an idea to an international centre
  • Establishment of an international board
  • Hiring a managing director
  • ICARS goes live
Participants in the initial workshop leading to the concept note:

CGIAR: John McDermott, Dieter Schillinger, Barbara Wieland, Jeff Waage,

World Bank: Jürgen Voegele, Franck Cesar Jean Berthe, Jonathan Wadsworth

Denmark: Birgit Nørrung, Anders Dalsgaard, (UC); Flemming Bager, Frank Aarestrup (DTU); Kåre Mølbak, Peter Lawætz Andersen (SSI); Wieke Edinger, Elisabeth Okholm Nielsen, Per Henrik Henriksen (DVFA); Jesper Wulff Pedersen, Mette Hulstrøm, Ministry of Environment and Food, Christina Holton Moloney, Ministry of Health
Thank you for your attention

We look forward to continuing the journey with you!